Ronotsit solution for infection. 1000mg/4ml amp. 4 ml No. 5

Pharmacological properties

Pharmacodynamics. tsitikolin stimulates biosynthesis of structural phospholipids of membranes of neurons that is confirmed with data of magnetic and resonant spectroscopy. tsitikolin improves functioning of such membrane mechanisms as ionic pumps and receptors without which regulation normal carrying out nervous impulses is impossible. thanks to the stabilizing action on a membrane of neurons tsitikolin shows antiedematous effects which promote a wet brain reabsorption.

Pilot studies showed that tsitikolin inhibits activation of some phospholipases (A1, A2, C and D), reducing education of free radicals, prevents destruction of membrane systems and keeps antioxidant protective systems, such as glutathione.

Tsitikolin keeps a neural stock of energy, inhibits apoptosis and stimulates synthesis of acetylcholine.

it is Experimentally proved that tsitikolin also has preventive neurotyre-tread effect in focal ischemia of a brain.

It was reported that tsitikolin authentically raises indicators of functional recovery at patients with an acute disorder of cerebral circulation that matches delay of growth of an ischemic brain damage according to neuroimaging. At patients with a craniocereberal injury tsitikolin accelerates restoration and reduces duration and intensity of a posttraumatic syndrome.

Tsitikolin increases the level of attention and consciousness, promotes reduction of severity of amnesia, the cognitive and neurologic disorders connected with brain ischemia.

Pharmacokinetics. Tsitikolin is well absorbed after peroral, in oil and in/in introductions. Sincaline level in blood plasma considerably increases after introduction in the above-mentioned ways. Absorption after oral introduction almost full, bioavailability practically same, as well as at in in use.

Depending on a way of introduction, medicament is metabolized in intestines, a liver to sincaline and cytidine. After introduction tsitikolin it is widely distributed in structures of a brain with fast inclusion of fraction of sincaline in structural phospholipids and fractions of cytidine in cytidine nucleotides and nucleic acids. Having reached a brain, tsitikolin it is built in cellular, cytoplasmic and mitochondrial membranes, participating in creation of fraction of phospholipids.

in urine and Calais (3%). About 12% of a dose are removed with CO ₂ expired air. In removal of medicament with urine allocate two phases: the first phase — about 36 h in which clearance rate quickly decreases and the second phase in which clearance rate decreases much more slowly. The same staging is observed at removal with CO ₂ , clearance rate with the exhaled CO ₂ quickly decreases approximately in 15 h, then it decreases much more slowly.

Indication

Stroke, sharp phase of disturbances of cerebral circulation and treatment of complications and consequences of disturbances of cerebral circulation; craniocereberal injury and its neurologic complications; cognitive disturbances and behavior disorders owing to chronic vascular and degenerative brain disorders.

Use

Drug is used for in/in or introductions in oil, in/in appoint in shape slow in/in an injection (within 3–5 min. depending on the appointed dose) or in/in by drop infusion (40–60 drops a minute).

Recommended dose for adults — 500–2000 mg/days depending on weight of a condition of the patient.

Maximum daily dose — 2000 mg.

At acute and medical emergencies when prescribing medicament in the first 24 h

Term of treatment depends on the course of the disease and is defined by the doctor. it is not required by

For patients of advanced age of dose adjustment to p.

to all in/in isotonic solutions and also to hypertensive solutions of glucose.

for single use. Solution needs to be entered at once after opening of an ampoule. Unused solution should be destroyed.

In need of treatment continues to be applied tsitikolin in the form of solution to oral administration.

Children. There are no sufficient data concerning use of medicament for children.

Contraindication

Hypersensitivity to any component of drug. the raised tone of parasympathetic nervous system.

Side effects

It is very rare (1/10,000) (including messages of patients).

from the central and peripheral nervous system: severe headache, vertigo, hallucinations.

from a cardiovascular system: AG, arterial hypotension, tachycardia.

from a respiratory system: asthma.

from digestive system: nausea, vomiting, diarrhea.

from skin: hyperaemia, allergic rash, rash, purpura, small tortoiseshell, itching, Quincke's disease, acute anaphylaxis.

General reactions: fever, hypostasis, changes in the injection site.

Special instructions

in case of persistent intracranial bleeding the medicament is recommended to be administered in the form of very slow in/in infusion (30 drops a minute) and not to exceed a daily dose of 1000 mg.

Use during pregnancy or feeding by a breast. Sufficient data on use of a tsitikolin for pregnant women are absent. It is possible to use medicament during pregnancy and feeding by a breast only when the expected advantage for mother exceeds possible risk for a fruit or the child.

Data on penetration of a tsitikolin into breast milk are absent.

Ability to influence speed of response at control of vehicles or other mechanisms. Tsitikolin does not affect ability to run vehicles and to work with difficult mechanisms.

Interaction

should not use medicament along with the medicaments containing Meclofenoxatum. enhances effect of a levodopa.

Incompatibility. Not to apply the solvents which are not specified in the section USE.

Overdose

. considering hypotoxicity of drug, poisoning probability low, even at accidental exceeding therapeutic doses.

Storage conditions

At a temperature not above 25 °C.